Intravenous itraconazole

Douglas Slain, Phillip Rogers, John D. Cleary, Stanley W. Chapman

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

OBJECTIVE: To review the pharmacology, mycology, chemistry, pharmacokinetics, efficacy, safety, tolerability, dosage, administration, and economic issues of intravenous itraconazole. DATA SOURCES: A MEDLINE search from 1978 to June 2000 of the English-language literature and an extensive review of meeting abstracts was conducted. Due to the paucity of published information concerning the pharmacokinetics, efficacy, and safety of the intravenous formulation of intravenous itraconazole, additional information was obtained from the manufacturer. DATA EXTRACTION: Data from in vitro and preclinical studies, as well as Phase II and III clinical trials, were included. DATA SYNTHESIS: The triazole antifungal agent itraconazole is available in a cyclodextrin-based intravenous formulation. Intravenous itraconazole is indicated for the treatment of pulmonary and extrapulmonary blastomycosis; histoplasmosis, including chronic cavitary pulmonary disease and disseminated, nonmeningeal histoplasmosis; and pulmonary and extrapulmonary aspergillosis in patients who are intolerant of or who are refractory to amphotericin B. This formulation provides quicker and more consistent therapeutic concentrations than the oral formulations. Clinical data comparing the efficacy of intravenous itraconazole with that of amphotericin B are lacking. CONCLUSIONS: Intravenous itraconazole offers a less toxic alternative for patients with pulmonary and extrapulmonary blastomycosis, histoplasmosis, and aspergillosis who cannot receive oral medications or who are intolerant of or refractory to amphotericin B.

Original languageEnglish (US)
Pages (from-to)720-729
Number of pages10
JournalAnnals of Pharmacotherapy
Volume35
Issue number6
DOIs
StatePublished - Jan 1 2001

Fingerprint

Itraconazole
Histoplasmosis
Amphotericin B
Blastomycosis
Pharmacokinetics
Mycology
Pulmonary Aspergillosis
Safety
Lung
Phase III Clinical Trials
Phase II Clinical Trials
Triazoles
Aspergillosis
Antifungal Agents
Poisons
Cyclodextrins
MEDLINE
Lung Diseases
Language
Economics

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

Slain, D., Rogers, P., Cleary, J. D., & Chapman, S. W. (2001). Intravenous itraconazole. Annals of Pharmacotherapy, 35(6), 720-729. https://doi.org/10.1345/aph.10262

Intravenous itraconazole. / Slain, Douglas; Rogers, Phillip; Cleary, John D.; Chapman, Stanley W.

In: Annals of Pharmacotherapy, Vol. 35, No. 6, 01.01.2001, p. 720-729.

Research output: Contribution to journalArticle

Slain, D, Rogers, P, Cleary, JD & Chapman, SW 2001, 'Intravenous itraconazole', Annals of Pharmacotherapy, vol. 35, no. 6, pp. 720-729. https://doi.org/10.1345/aph.10262
Slain D, Rogers P, Cleary JD, Chapman SW. Intravenous itraconazole. Annals of Pharmacotherapy. 2001 Jan 1;35(6):720-729. https://doi.org/10.1345/aph.10262
Slain, Douglas ; Rogers, Phillip ; Cleary, John D. ; Chapman, Stanley W. / Intravenous itraconazole. In: Annals of Pharmacotherapy. 2001 ; Vol. 35, No. 6. pp. 720-729.
@article{baab5ff2739d4b51a60b9026831bfb8f,
title = "Intravenous itraconazole",
abstract = "OBJECTIVE: To review the pharmacology, mycology, chemistry, pharmacokinetics, efficacy, safety, tolerability, dosage, administration, and economic issues of intravenous itraconazole. DATA SOURCES: A MEDLINE search from 1978 to June 2000 of the English-language literature and an extensive review of meeting abstracts was conducted. Due to the paucity of published information concerning the pharmacokinetics, efficacy, and safety of the intravenous formulation of intravenous itraconazole, additional information was obtained from the manufacturer. DATA EXTRACTION: Data from in vitro and preclinical studies, as well as Phase II and III clinical trials, were included. DATA SYNTHESIS: The triazole antifungal agent itraconazole is available in a cyclodextrin-based intravenous formulation. Intravenous itraconazole is indicated for the treatment of pulmonary and extrapulmonary blastomycosis; histoplasmosis, including chronic cavitary pulmonary disease and disseminated, nonmeningeal histoplasmosis; and pulmonary and extrapulmonary aspergillosis in patients who are intolerant of or who are refractory to amphotericin B. This formulation provides quicker and more consistent therapeutic concentrations than the oral formulations. Clinical data comparing the efficacy of intravenous itraconazole with that of amphotericin B are lacking. CONCLUSIONS: Intravenous itraconazole offers a less toxic alternative for patients with pulmonary and extrapulmonary blastomycosis, histoplasmosis, and aspergillosis who cannot receive oral medications or who are intolerant of or refractory to amphotericin B.",
author = "Douglas Slain and Phillip Rogers and Cleary, {John D.} and Chapman, {Stanley W.}",
year = "2001",
month = "1",
day = "1",
doi = "10.1345/aph.10262",
language = "English (US)",
volume = "35",
pages = "720--729",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "6",

}

TY - JOUR

T1 - Intravenous itraconazole

AU - Slain, Douglas

AU - Rogers, Phillip

AU - Cleary, John D.

AU - Chapman, Stanley W.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - OBJECTIVE: To review the pharmacology, mycology, chemistry, pharmacokinetics, efficacy, safety, tolerability, dosage, administration, and economic issues of intravenous itraconazole. DATA SOURCES: A MEDLINE search from 1978 to June 2000 of the English-language literature and an extensive review of meeting abstracts was conducted. Due to the paucity of published information concerning the pharmacokinetics, efficacy, and safety of the intravenous formulation of intravenous itraconazole, additional information was obtained from the manufacturer. DATA EXTRACTION: Data from in vitro and preclinical studies, as well as Phase II and III clinical trials, were included. DATA SYNTHESIS: The triazole antifungal agent itraconazole is available in a cyclodextrin-based intravenous formulation. Intravenous itraconazole is indicated for the treatment of pulmonary and extrapulmonary blastomycosis; histoplasmosis, including chronic cavitary pulmonary disease and disseminated, nonmeningeal histoplasmosis; and pulmonary and extrapulmonary aspergillosis in patients who are intolerant of or who are refractory to amphotericin B. This formulation provides quicker and more consistent therapeutic concentrations than the oral formulations. Clinical data comparing the efficacy of intravenous itraconazole with that of amphotericin B are lacking. CONCLUSIONS: Intravenous itraconazole offers a less toxic alternative for patients with pulmonary and extrapulmonary blastomycosis, histoplasmosis, and aspergillosis who cannot receive oral medications or who are intolerant of or refractory to amphotericin B.

AB - OBJECTIVE: To review the pharmacology, mycology, chemistry, pharmacokinetics, efficacy, safety, tolerability, dosage, administration, and economic issues of intravenous itraconazole. DATA SOURCES: A MEDLINE search from 1978 to June 2000 of the English-language literature and an extensive review of meeting abstracts was conducted. Due to the paucity of published information concerning the pharmacokinetics, efficacy, and safety of the intravenous formulation of intravenous itraconazole, additional information was obtained from the manufacturer. DATA EXTRACTION: Data from in vitro and preclinical studies, as well as Phase II and III clinical trials, were included. DATA SYNTHESIS: The triazole antifungal agent itraconazole is available in a cyclodextrin-based intravenous formulation. Intravenous itraconazole is indicated for the treatment of pulmonary and extrapulmonary blastomycosis; histoplasmosis, including chronic cavitary pulmonary disease and disseminated, nonmeningeal histoplasmosis; and pulmonary and extrapulmonary aspergillosis in patients who are intolerant of or who are refractory to amphotericin B. This formulation provides quicker and more consistent therapeutic concentrations than the oral formulations. Clinical data comparing the efficacy of intravenous itraconazole with that of amphotericin B are lacking. CONCLUSIONS: Intravenous itraconazole offers a less toxic alternative for patients with pulmonary and extrapulmonary blastomycosis, histoplasmosis, and aspergillosis who cannot receive oral medications or who are intolerant of or refractory to amphotericin B.

UR - http://www.scopus.com/inward/record.url?scp=0035006398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035006398&partnerID=8YFLogxK

U2 - 10.1345/aph.10262

DO - 10.1345/aph.10262

M3 - Article

VL - 35

SP - 720

EP - 729

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 6

ER -